Találati lista | Tudóstér

001-es BibID:	BIBFORM020653
Első szerző:	Kiss Emese (belgyógyász, immunológus)
Cím:	Reduced flow-mediated vasodilation as a marker for cardiovascular complications in lupus patients / Kiss E., Soltesz P., Der H., Kocsis Z., Tarr T., Bhattoa H., Shoenfeld Y., Szegedi G.
Dátum:	2006
Megjegyzések:	Systemic lupus erythematosus is associated with accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Objectives were to determine endothelial dysfunction with a non-invasive method in lupus patients and to analyse correlation with risk factors and atherosclerotic complications. Sixty-one SLE patients and 26 healthy age- and sex-matched control subjects were entered into the study. The diameters of brachial artery at rest, during reactive hyperaemia, and after glyceril trinitrate administration, as well as the intima-media thickness of the common carotid artery were measured using high-resolution B-mode ultrasonography. Demographic characteristics, lipid profile, paraoxonase activity, concentration of anti-phospholipid antibodies and anti-oxLDL were assessed together with atherosclerotic complications. The endothelium dependent vasodilation (FMD) was significantly impaired in SLE patients as compared to controls. The absolute difference of vessel diameter (Deltad) was 0.25+/-0.15 mm vs. 0.38+/-0.16 mm (p=0.001), and Deltad as in percent of the rest diameter was 7.31+/-5.2% vs. 9.86+/-3.87% (p=0.013) in lupus patients and controls, respectively. Nitrate mediated dilation (NMD) did not differ. FMD negatively correlated with age, systolic and diastolic blood pressure in SLE, but did not show significant correlation with the other examined parameters. However, FMD significantly differed between SLE patients with (5.54+/-4.36%) and without (8.81+/-5.28%) cardiovascular complications (p=0.01). The determination of flow-mediated vasodilation is a useful method to detect endothelial dysfunction in lupus patients, as reduced capacity of brachial artery may distinguish between SLE patients and healthy subjects, as well as lupus patients with and without atherosclerotic vascular complications.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Journal of Autoimmunity. - 27 : 4 (2006), p. 211-217. -
További szerzők:	Soltész Pál (1961-) (belgyógyász, kardiológus) Dér Henrietta (1977-) (orvos) Kocsis Zsolt (1987-) (orvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon:

001-es BibID:	BIBFORM001205
035-os BibID:	PMID:17916982
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:	2007
Megjegyzések:	Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban SLE antiphospholipid antibodies thrombotic manifestation APS Follow-up LAC Primary prophylaxis acetylsalicylic acid antithrombocytic agent beta2 glycoprotein 1 antibody cardiolipin antibody coumarin lupus anticoagulant phospholipid antibody adult antiphospholipid syndrome article cerebrovascular accident cohort analysis controlled study data base deep vein thrombosis disease association disease course drug efficacy female follow uphigh risk population history of medicine human international normalized ratio lung embolism major clinical study male medical record prevalence prophylaxis prospective study stroke systemic lupus erythematosus thrombosis transient ischemic attack Adult Antibodies, Antiphospholipid Antibody Specificity Anticoagulants Antiphospholipid Syndrome Aspirin Cohort Studies Female Follow-Up Studies Humans Lupus Erythematosus, Systemic Male Middle Aged Thrombosis Time Factors egyetemen (Magyarországon) készült közlemény
Megjelenés:	Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:	Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon: